Alan J Russell has sold EWTX and made no open-market buys since Sep 2021

Russell Alan J is a corporate insider and individual who serves as Chief Scientific Officer (CSO) and a director at Edgewise Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing therapies for serious muscle disorders.( He has been confirmed in this executive role through company employment documentation, which notes that he reports directly to the Chief Executive Officer and performs the customary duties of the CSO for the organization.( As an insider, Russell Alan J has been involved in significant equity transactions in Edgewise Therapeutics stock, including the sale of 100,000 shares of common stock in August 2025, after which he directly held 23,400 shares in the company.(

Under the name Alan J. Russell, Ph.D., he is described as a co‑founder, Chief Scientific Officer, and member of the board of directors of Edgewise Therapeutics.( His prior industry experience includes senior roles at GlaxoSmithKline, where he served as Vice President and Head of the Muscle Metabolism Discovery Performance Unit, leading discovery and development programs for patients with impaired muscle function, and at Cytokinetics Inc., where he co‑invented the direct muscle sensitizers tirasemtiv and reldesemtiv for amyotrophic lateral sclerosis (ALS).( He holds a B.Pharm. in Pharmacy and Pharmacology and a Ph.D. in Cell Biology and Gene Therapy from the University of Bath (UK) and completed postdoctoral training at Stanford University School of Medicine, and has spent roughly two decades in the discovery and development of medicines to improve skeletal muscle health.(

Written by Perplexity from public sources.